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Abstract: The tumor-suppressor protein p16 is paradoxically overexpressed in cervical cancer
(CC). Despite its potential as a biomarker, its clinical value and the reasons for its failure in
tumor suppression remain unclear. Our purpose was to determine p16 clinical and biological
significance in CC. p16 expression pattern was examined by immunohistochemistry in 78 CC cases
(high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix
–SCCCs). CC cell proliferation and invasion were monitored by real-time cell analysis and Transwell®
invasion assay, respectively. Cytoplasmic p16 interactors were identified from immunoprecipitated
extracts by liquid chromatography-tandem mass spectrometry, and colocalization was confirmed by
double-immunofluorescence. We observed that SCCCs showed significantly more cytoplasmic than
nuclear p16 expression than HSILs. Importantly, nuclear p16 absence significantly predicted poor
outcome in SCCC patients irrespective of other clinical parameters. Moreover, we demonstrated that
cytoplasmic p16 interacted with CDK4 and other unreported proteins, such as BANF1, AKAP8 and
AGTRAP, which could sequester p16 to avoid nuclear translocation, and then, impair its anti-tumor
function. Our results suggest that the absence of nuclear p16 could be a diagnostic biomarker
between HSIL and SCCC, and an independent prognostic biomarker in SCCC; and explain why p16
overexpression fails to stop CC growth.
Keywords: cytoplasmic p16; nuclear p16; subcellular location; predictive biomarker;
squamous cell carcinoma of the cervix; high-grade squamous intraepithelial lesion; cervical cancer
1. Introduction
Squamous cell carcinoma of the cervix (SCCC) accounts for 70–80% of all cervical cancer (CC)
cases, which is the fourth most frequent cancer type in women worldwide [1], with a 5-year survival
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Int. J. Mol. Sci. 2020, 21, 2125 2 of 16
of 57–67% in Europe [2]. SCCC pathogenesis is a slow multi-stage process: when a high-risk
human papillomavirus (HR-HPV) infection—present in 99.7% of cases [2,3]—persists in dividing cells,
these can originate a high-grade squamous intraepithelial lesion (HSIL); if, additionally, some molecular
alterations occur, tumor cells extend beyond the basement membrane of the epithelium, and then an
invasive carcinoma appears [3,4]. Unfortunately, early SCCC is often asymptomatic and detected at an
advanced stage when treatments are ineffective. Developments in early diagnosis are therefore much
needed [1]. Currently, the standard method for SCCC diagnosis has many limitations because it is
mainly based on subjective interpretation of histological changes in cervical tissue [2,4–6]. Intriguingly,
as CC development seems to be a continuous process, it is quite difficult to morphologically distinguish
an HSIL which has begun to invade and an SCCC which has just penetrated the basement membrane.
However, these apparently similar tumors display very different clinical behaviors. Women with HSIL
are treated with surgery that is usually successful, with more than 85% of patients being cured [7];
those with SCCC receive surgery plus chemoradiotherapy, but unfortunately, half of them die from
the disease [2]. An accurate diagnosis is therefore crucial for the successful clinical management of
these patients.
Recently, an HPV DNA test has been introduced as a screening tool; this has proved to be much
more sensitive than traditional methods [2], indicating that molecular biomarkers are very informative
and of great utility. Indeed, they are objective, quantitative and easily reproducible in all hospitals and
laboratories, for many tumor types [8–10]. However, to date, no molecular panel has been available for
SCCC, in contrast to other malignancies, such as breast [8,11], lung [12] and colorectal [13] cancers,
so there is an urgent need for molecular biomarkers that will enable early diagnosis, prognosis and
targeted therapy for SCCC [14]. A better understanding of the molecular mechanisms leading to SCCC
could help us develop better clinical strategies to improve patients’ likelihood of survival. In fact,
the European Society of Medical Oncology has recommended that more research be undertaken to
identify molecular biomarkers in CC [2].
The cyclin-dependent kinase inhibitor 2A protein, also called p16, is a well-known
tumor-suppressor protein which is down-regulated in many tumors, and is involved in regulating cell
cycle, senescence, apoptosis, cell invasion and angiogenesis [3,5,15]. In spite of these well-recognized
tumor-suppressor properties, p16 expression paradoxically increases with the severity of the cervical
lesion [3,5,14,16], and has been then proposed as a useful marker for identifying such lesions [5,17–20].
In fact, its ancillary use in cervical cytology has improved the accuracy of histological diagnosis [5,21],
mainly in premalignant lesions [4]. However, the specificity of p16 has been insufficiently studied in
SCCC [18], and its prognostic value remains controversial [3,5,14].
As there is a lack of consensus and clear guidelines regarding the use of p16 expression in routine
clinical management of SCCC [2,5,19], we aimed to shed some light on the clinical utility and biological
significance of p16 overexpression during SCCC progression.
2. Results
2.1. Expression Pattern and Clinical Relevance of p16 in SCCC Patients
Global p16 expression was examined in our series of 29 HSILs and 49 SCCCs, taking into account
the criteria which are routinely used in the clinical practice. We observed that SCCC tumors had
a significantly higher level of p16 expression than did HSILs (p < 0.001) (Figure 1A and Table 1).
No statistical association was found between global p16 expression and pathological variables (data
not shown). Interestingly, significant associations between a high level of global p16 expression
and good prognosis and outcome were found in SCCC patients (Figure 1B), independent of other
clinical parameters crucial in SCCC prognosis, such as age, stage and vascular invasion (Figure 1C
and Figure S1). Indeed, Cox analyses showed that strong expression of p16 had a protective effect
against relapse and death (hazard ratios 0.079 and 0.031 for progression-free survival (PFS) and overall
survival (OS), respectively) (Figure 1C). These results contribute to the paradox of p16 overexpression
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in SCCC, since a tumor-suppressor protein which significantly adds to a good outcome is overall
overexpressed in this aggressive cancer type.
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Figure 1. Global p16 expression in cervical tumors. (A) Immunohistochemical expression of p16 was 
examined in a series of 29 high-grade squamous intraepithelial lesions (HSILs) and 49 squamous cell 
carcinomas of the cervix (SCCCs) (*** p < 0.001). Representative images are shown at 200× 
magnification, and details are highlighted at 400×. (B) Association between global p16 expression 
and progression-free survival (PFS) and overall survival (OS) in SCCC patients. (C) Multivariate 
analysis showing the independent association between p16 expression and PFS (left) or OS (right), 
regardless of vascular invasion, stage and age of SCCC patients. (CI, confidence interval). 
  
Figure 1. Global p16 expression in cervical tumors. (A) Immunohistochemical expression of p16 was
examined in a series of 29 high-grade squamous intraepithelial lesions (HSILs) and 49 squamous cell
carcinomas of the cervix (SCCCs) (*** p < 0.001). Representative images are show at 200× agnification,
and details are highlighted at 400×. (B) Association between global p16 expression and progression-free
survival (PFS) and overall survival (OS) in SCCC patients. (C) Multivariate analysis showing the
independent association between p16 expression and PFS (left) or OS (right), regardless of vascular
invasion, stage and age of SCCC patients. (CI, confidence interval).
Table 1. Distribution of p16 expression and subcellular location in our series of 78 cervical tumors.
Number and percentage of high-grade squamous intraepithelial lesions (HSILs) (n = 29) and squamous
cell carcinomas of the cervix (SCCCs) (n = 49) patients with negative (0), weak (1), moderate (2)
and strong (3) immunohistochemical expression of global, nuclear and cytoplasmic p16 protein
levels. The cytoplasmic/nuclear p16 ratio was calculated by dividing cytoplasmic by nuclear p16
immunohistochemical score.
Global p16 No. of HSILs No. of SCCCs
0 1 (3%) 2 (4%)
1 2 (7%) 3 (6%)
2 17 (59%) 6 (12%)
3 9 (31%) 38 (78%)
Nuclear p16
0 1 (3%) 3 (6%)
1 4 (14%) 3 (6%)
2 10 (34%) 16 (33%)
3 14 (48%) 27 (55%)
Cytoplasmic p16
0 1 (3%) 3 (6%)
1 8 (28%) 3 (6%)
2 19 (66%) 8 (16%)
3 1 (3%) 35 (71%)
Cyt/nuc p16 ratio
<1 17 (59%) 6 (12%)
=1 8 (26%) 21 (43%)
>1 4 (14%) 22 (45%)
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In order to shed some light on this controversy, we focused on p16 subcellular location,
and observed that SCCC tumors showed stronger cytoplasmic than nuclear staining than the
HSIL samples, regardless of the global expression of the protein (Figure 2A and Table 1). Indeed,
SCCC samples displayed a significantly higher cytoplasmic/nuclear p16 ratio than HSIL (p < 0.001).
This finding suggests that not only p16 expression, but also its subcellular location, could be diagnostic
biomarkers which can distinguish between HSIL and SCCC.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 18 
 
 
Figure 2. Subcellular location of p16 in cervical tumors. (A) Representative images of p16 staining in 
3 high-grade intraepithelial lesions (HSILs) and 3 squamous carcinomas of the cervix (SCCCs) at 
400× magnification showing that SCCC samples (n = 49) showed stronger cytoplasmic than nuclear 
p16 expression than HSIL (n = 29), regardless of the degree of global p16 staining (strong, moderate 
or low). Note p16 negativity in the nuclei of the low p16-expressing SCCC sample. The ratio 
cytoplasmic to nuclear (cyt/nuc) p16 expression was calculated by dividing p16 
immunohistochemical score in each subcellular compartment. The horizontal line in the histogram 
shows equal amounts of cytoplasmic and nuclear p16 (ratio cyt/nuc p16 = 1) (*** p < 0.001). (B) 
Association between p16 subcellular location and overall survival (OS) in SCCC patients. (C) 
Multivariate analysis revealed an independent association between p16 subcellular location and OS, 
regardless of vascular invasion, stage and age of SCCC patients. (CI, confidence interval). 
2.2. p16 Subcellular Location in SCCC Cell Lines 
p16 expression pattern was also interrogated in SCCC cell lines. Western blot (Figure 3A) and 
immunofluorescence (Figure 3B) revealed that C-33A cells expressed p16 in both the nucleus and the 
cytoplasm, while SiHa cells only expressed it in the cytoplasm. Similar to what we observed in SCCC 
tumors, this differential subcellular location could affect cell aggressiveness, as SiHa had greater 
proliferative (Figure 3C) and invasive (Figure 3D) properties than did C-33A. These abilities were 
also examined in the HeLa cell line (Figure S2), which was derived from a cervical adenocarcinoma, 
with nearly identical clinical features to SCCC [22]. Interestingly, we found a very similar pattern of 
p16 expression and growth and invasive capacities in HeLa and SiHa cells, indicating that the 
absence of nuclear location of p16 is related to CC aggressiveness. 
Figure 2. Subcellular location of p16 in cervical tumors. (A) Representative images of p16 staining in 3
high-grade intraepithelial lesions (HSILs) and 3 squamous carcinomas of the cervix (SCCCs) at 400×
magnification showing that SCCC samples (n = 49) showed stronger cytoplasmic than nuclear p16
expression than HSIL (n = 29), regardless of the degree of global p16 staining (strong, moderate or low).
Note p16 negativity in the nuclei of the low p16-expressing SCCC sample. The ratio cytoplasmic to
nuclear (cyt/nuc) p16 expression was calculated by dividing p16 immunohistochemical score in each
subcellular compartment. The horizontal line in the histogram shows equal amounts of cytoplasmic and
nuclear p16 (ratio cyt/nuc p16 = 1) (*** p < 0.001). (B) Association between p16 subcellular location and
overall survival (OS) in SCCC patients. (C) Multivariate analysis revealed an independent association
between p16 subcellular location and OS, regardless of vascular invasion, stage and age of SCCC
patients. (CI, confidence interval).
Furthermore, although no significant association was found between nuclear or cytoplasmic p16
expression and pathological variables (data not shown), the absence of nuclear p16, observed in only
6% of SCCC patients though (Table 1), was significantly associated with a very poor outcome (p =
0.031) (Figure 2B and Table S1). Moreover, this association was significantly independent of clinical
parameters like age, stage or vascular invasion (p = 0.002); and we found that the lack of nuclear p16
significantly increased the risk of death by more than 200-fold (Figure 2C).
These findings indicate that although p16 is globally overexpressed in SCCC, it is not mainly
located in the nucleus, where it could exert its tumor-suppressor functions. Therefore, these results
could explain the p16 paradox in SCCC.
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2.2. p16 Subcellular Location in SCCC Cell Lines
p16 expression pattern was also interrogated in SCCC cell lines. Western blot (Figure 3A) and
immunofluorescence (Figure 3B) revealed that C-33A cells expressed p16 in both the nucleus and
the cytoplasm, while SiHa cells only expressed it in the cytoplasm. Similar to what we observed in
SCCC tumors, this differential subcellular location could affect cell aggressiveness, as SiHa had greater
proliferative (Figure 3C) and invasive (Figure 3D) properties than did C-33A. These abilities were
also examined in the HeLa cell line (Figure S2), which was derived from a cervical adenocarcinoma,
with nearly identical clinical features to SCCC [22]. Interestingly, we found a very similar pattern of
p16 expression and growth and invasive capacities in HeLa and SiHa cells, indicating that the absence
of nuclear location of p16 is related to CC aggressiveness.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 18 
 
 
Figure 3. p16 subcellular location in SCCC cell lines. (A) Nuclear and cytoplasmic protein fractions of 
C-33A and SiHa were separately subjected to western blot to check p16 expression. GAPDH and 
Histone H3 were used as loading controls of each subcellular fraction. Numbers indicate the ratio of 
p16 signal relative to that in the loading control, measured by densitometry. (B) p16 expression was 
examined by immunofluorescence in C-33A and SiHa cells. Images were acquired at 400× 
magnification. (C) Cell proliferation of C-33A and SiHa cell lines was measured by real-time cell 
analysis for 7 days (* p < 0.05). (D) Cell invasion of C-33A and SiHa cell lines was examined by their 
ability to penetrate a Matrigel® layer for 3 days. Images were acquired at 50× magnification. 
2.3. Cytoplasmic p16 Interactome in SCCC 
To understand why p16 is mainly confined to the cytoplasm in aggressive SCCC tumors, we 
hypothesized that it could be sequestered by other proteins to form large macromolecular complexes 
in order to avoid nuclear translocation, as has been described in other tumor types [15]. To test this 
hypothesis, we first examined the conformation of native p16 by western blot under non-denaturing 
conditions. We observed a band in SiHa, but not in C-33A, which may indicate a differential 3D 
conformation of native p16 (Figure 4A). This finding suggested that p16 could actually be bound to 
other proteins that sequester it in the cytoplasm. Therefore, cytoplasmic p16 was 
immunoprecipitated from SiHa cells, which lacked nuclear p16 (Figure 3A). Figure 4B shows 
immunoprecipitation efficiency regarding the pull-down of p16 and its interactors, as one of the 
well-known proteins that interacts with p16, the cyclin-dependent kinase 4 (CDK4) [15], was also 
detected in our immunoprecipitated extract (Figure 4B). To be confident in the identification of p16 
interactors, those extracts were digested by taking a dual approach—in-gel and in-solution 
digestion—and then subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
(Table S2). Data mining of LC-MS/MS-generated proteomic data revealed that 16 proteins were 
simultaneously identified in both extracts pulled down with the anti-p16 antibody, but not with IgG 
(Table 2). They were proposed to be at least a part of the cytoplasmic p16 interactome in SiHa cells 
with a false-discovery rate (FDR) < 0.01. It is worth mentioning that no protein from HPV was found 
to be bound to cytoplasmic p16. Importantly, we observed that the vast majority of those human 
interacting proteins had not been previously reported in the BioGRID interaction repository, which 
currently contains 229 interactors for p16 (January 2020). The only two proteins found to be common 
to the BioGRID list and the immunoprecipitated extracts digested in-gel and in-solution were CDK4 
and C1QBP (Figure S3). Our findings therefore include 14 new potentially interacting cytoplasmic 
p16 proteins. 
Figure 3. p16 subcellular location in SCCC cell lines. (A) Nuclear and cytoplasmic protein fractions
of C-33A and SiHa were separately subjected to western blot to check p16 expression. GAPDH and
Histone H3 were used as loading controls of each subcellular fraction. Numbers indicate the ratio of
p16 signal relative to that in the loading control, measured by densitometry. (B) p16 expression was
examined by immunofluorescence in C-33A and SiHa cells. Images were acquired at 400×magnification.
(C) Cell proliferation of C-33A and SiHa cell lines was measured by real-time cell analysis for 7 days
(* p < 0.05). (D) Cell invasion of C-33A and SiHa cell lines was examined by their ability to penetrate a
Matrigel® layer for 3 days. Images were acquired at 50×magnification.
2.3. Cytoplasmic p16 Interactome in SCCC
To understand why p16 is mainly confined to the cytoplasm in aggressive SCCC tumors,
we hypothesized that it could be sequestered by other proteins to form large macromolecular
complexes in order to avoid nuclear t anslocation, as has been describ d in other tumo types [15].
To test this hypothesis, we first examined the co formation of native p16 by western blo under
non-denaturing conditions. We observed a band in SiHa, but not in C-33A, which may indicate
a differe tial 3D conform tio of ative p16 (Figure 4A). This finding sugges d that p16 could
actually be bound o other proteins that sequester it in th cytopl sm. Therefore, cytoplasmic p16
was immunoprecipitated from SiHa cells, w ich lacked nuclear p16 (Figure 3A). Figure 4B show
ion efficiency regarding the pull- own of p16 and its interactors, as one of the
well-k wn prote ns that nteracts with p16, the cyclin-dependent kinase 4 (CDK4) [15], was also
detected in our immunoprecipitated extract (Figure 4B). To be confident in the identification of
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p16 interactors, those extracts were digested by taking a dual approach—in-gel and in-solution
digestion—and then subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS)
(Table S2). Data mining of LC-MS/MS-generated proteomic data revealed that 16 proteins were
simultaneously identified in both extracts pulled down with the anti-p16 antibody, but not with
IgG (Table 2). They were proposed to be at least a part of the cytoplasmic p16 interactome in SiHa
cells with a false-discovery rate (FDR) < 0.01. It is worth mentioning that no protein from HPV was
found to be bound to cytoplasmic p16. Importantly, we observed that the vast majority of those
human interacting proteins had not been previously reported in the BioGRID interaction repository,
which currently contains 229 interactors for p16 (January 2020). The only two proteins found to be
common to the BioGRID list and the immunoprecipitated extracts digested in-gel and in-solution
were CDK4 and C1QBP (Figure S3). Our findings therefore include 14 new potentially interacting
cytoplasmic p16 proteins.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 18 
 
 
Figure 4. Cytoplasmic p16 interactors in SiHa cells. (A) Native form of p16 protein was examined in 
both C-33A and SiHa cell lines by western blot under non-denaturing conditions. Arrows point to 
the proteins of interest, while the arrowhead indicates a different 3D conformation of native p16 in 
SiHa, as compared with C-33A. α-tubulin was used as a loading control. (B) Exclusively cytoplasmic 
p16 was immunoprecipitated from SiHa cells, and efficiency was checked by western blot. 
Immunoprecipitated (IP) and unbound (UB) fractions upon incubation with IgG and anti-p16 
antibodies are shown. α-tubulin was used as a loading control. Immunoprecipitation of p16 
interactors was checked by incubating the same membrane with an anti-CDK4 antibody, a very 
well-known p16-interacting protein. The arrows indicate the proteins of interest. (C) Colocalization 
in the cytoplasm of SiHa cells of p16 (in green) and four interactors (in red), identified by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), was revealed by double 
immunofluorescence. Images were acquired at 400× magnification. 
Figure 4. ytoplas ic p16 interactors in Si a cells. ( ) ative for of p16 protein as exa ined in
both C-33 and SiHa cell lines by western blot under non-denaturing conditions. Arrows point to the
proteins of interest, while the arrowhead indicates a different 3D conformation of native p16 in SiHa,
as compared with C-33A. α-tubulin was used as a loading control. (B) Exclusively cytoplasmic p16 was
immunoprecipitated from SiHa cells, and efficiency was checked by western blot. Immunoprecipitated
(IP) and unbound (UB) fractions upon incubation with IgG and anti-p16 antibodies are shown. α-tubulin
was used as a loading control. Immunoprecipitation of p16 interactors was checked by incubating the
same membrane with an anti-CDK4 antibody, a very well-known p16-interacting protein. The arrows
indicate the proteins of interest. (C) Colocalization in the cytoplasm of SiHa cells of p16 (in green) and
four interactors (in red), identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS),
was revealed by double immunofluorescence. Images were acquired at 400×magnification.
Int. J. Mol. Sci. 2020, 21, 2125 7 of 16
Table 2. Cytoplasmic p16 interactome in SiHa cells. 16 proteins were simultaneously identified in two independent experiments through in-solution- and in-gel-digested
extracts from immunoprecipitated p16 in the SiHa cell line (false-discovery rate (FDR) < 0.01).
Protein Name UniProt ID Gene Name Brief Description
Cyclin-dependent kinase 4 P11802 CDK4 Ser/Thr-kinase which phosphorylates and inhibits members of the Rb protein family to allow dissociation of E2F,which is responsible for the progression through the G1 phase of the cell cycle.
Complement component 1 Q subcomponent-binding
protein, mitochondrial Q07021 C1QBP
Involved in inflammation and infection processes, ribosome biogenesis, protein synthesis in mitochondria,
regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. It is required for the nuclear
translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A-mediated apoptosis. Stabilizes
mitochondrial CDKN2A isoform smARF.
Type-1 angiotensin II receptor-associated protein Q6RW13 AGTRAP Negative regulator of type-1 angiotensin II receptor-mediated signaling.
A-kinase anchor protein 8 O43823 AKAP8
Anchoring protein which mediates the subcellular compartmentation of PKA type II. May help to deliver cyclin
D/E to CDK4 to facilitate cell cycle progression. Involved in nuclear retention of RPS6KA1 upon ERK activation
thus inducing cell proliferation. May be involved in recruitment of active CASP3 to the nucleus in apoptotic cells.
May act as a carrier protein of GJA1 for its transport to the nucleus.
THO complex subunit 4 E9PB61 ALYREF Export adapter involved in nuclear export of spliced and unspliced mRNA.
Barrier-to-autointegration factor O75531 BANF1 Plays fundamental roles in nuclear assembly, chromatin organization, gene expression and gonad development.Promotes integration of viral DNA into the host chromosome.
ATP-dependent RNA helicase DDX24 Q9GZR7 DDX24 ATP-dependent RNA helicase.
40S ribosomal protein S30 E9PR30 FAU Ubiquitin-like and ribosomal protein S30 fusion.
Heterogeneous nuclear ribonucleoprotein U-like protein 1 Q9BUJ2 HNRNPUL1 Represses transcription driven by several virus and cellular promoters.
Polyadenylate-binding protein 2 Q86U42 PABPN1 Involved in the 3
′-end formation of mRNA precursors by the addition of a poly(A) tail and various stages of mRNA
metabolism including nucleocytoplasmic trafficking.
cGMP-specific 3’,5’-cyclic phosphodiesterase O76074 PDE5A Hydrolysis of cGMP to 5′-GMP.
Pregnancy zone protein P20742 PZP Proteinase inhibition.
U5 small nuclear ribonucleoprotein 200 kDa helicase O75643 SNRNP200 RNA helicase essential for pre-mRNA splicing.
Serine/arginine repetitive matrix protein 1 Q8IYB3 SRRM1 Part of pre- and post-splicing multiprotein mRNP complexes involved in numerous pre-mRNA processing events.
Testis-specific Y-encoded-like protein 2 Q9H2G4 TSPYL2 May inhibit cell proliferation by inducing p53-dependent CDKN1A expression.
ATPase WRNIP1 Q96S55 WRNIP1 Modulator of DNA polymerase delta-mediated DNA synthesis.
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2.4. Colocalization of Cytoplasmic p16 and Interactors in SiHa Cells
Some of the cytoplasmic p16 interactors identified by LC-MS/MS were selected for further
examination by double immunofluorescence because of their involvement in other carcinogenic
processes [23–29]. As seen in Figure 4C, we found that CDK4, the A-kinase anchor protein 8 (AKAP8),
the barrier to autointegration factor (BANF1), and the type-1 angiotensin II receptor-associated protein
(AGTRAP) colocalized with p16 in the cytoplasm of SiHa cells, confirming that these proteins interact
with cytoplasmic p16 in SiHa cells.
3. Discussion
Although p16 overexpression is a potential biomarker for CC clinical management [5,17,18],
there is a lack of consensus [5,19] and standard guidelines [2] concerning its routine use. Similarly,
the biological significance of the paradoxical activation of this tumor-suppressor protein in CC is not
yet well understood.
We confirmed p16 overexpression in our series of 78 cervical tumors, as extensively
described [3,14,16,21], since strong p16 expression is a proven useful surrogate biomarker for tumors
with transcriptionally active HR-HPV [5]. Importantly, we found that p16 expression—and especially
the cytoplasmic/nuclear p16 ratio—significantly distinguished HSIL from SCCC. Our findings are
therefore evidence of the usefulness of p16 as a diagnostic biomarker between HSIL and SCCC,
as previously proposed [18,19]. In fact, it has facilitated inter-observer agreement and then has
improved the accuracy of traditional diagnostic methods based on histological observation in lower
grade lesions [4–6,21,30].
Notably, a high level of p16 expression was significantly associated with longer survival in
our SCCC series, irrespective of other clinical parameters such as age, stage and vascular invasion.
Although some reports have associated p16 overexpression with poor prognosis [3,14], our results
are consistent with those of a meta-analysis involving 1633 CC patients [5]. It is thought that
HR-HPV-related tumors are less genetically altered, and therefore tend to respond better to therapy
and to have improved outcome [5,15]. Here, we noticed that 6% of SCCCs had null or low p16 levels.
Although our sample number is limited, we have observed the same small proportion of p16 negative
SCCC patients than a recent report where such patients negative for global p16, which represented
only 4% of CC cases, had significantly worse OS [31].
It has been suggested that the lack of a standardized cut-off point for p16 overexpression could
have masked its true clinical value [5]. However, as it is difficult to establish a cut-off value in
subjectively evaluated immunohistochemical staining, the novelty of our study relies on the relevance
of p16 subcellular location. To date, p16 expression pattern remains controversial, because there is
no fundamental justification yet as to whether cytoplasmic/nuclear or only nuclear staining should
be taken as positive [15]. As other authors have found [5,32], there was no association between
p16 expression or location and pathological variables in our study, but we did find that the lack of
nuclear p16 allowed SCCC to acquire aggressive features both in tumors and in vitro. This interesting
finding goes some way to explaining the paradoxical p16 overexpression in SCCC. It is thought that
retinoblastoma (Rb) protein inhibition by HPV E7 protein triggers a negative feedback that leads to p16
overexpression, in a failed attempt to stop cell proliferation [3,5,15,17]. Our results could explain this
failure, since, although overexpressed, p16 would not be able to fulfil any anti-tumor function in the
cytoplasm. Cytoplasmic levels of some typical nuclear cell cycle regulators, such as p16, p27 and PTEN,
have been described and associated with tumor progression in uterine leiomyosarcomas, astrocytomas,
gastrointestinal stromal tumors and breast and colorectal cancer [15,17]. However, cytoplasmic p16
has been subtly examined in CC, found to be not significantly associated with the histological grade of
the lesion [17] and associated with a borderline-significantly worse two-year PFS in HSIL patients (p =
0.049) [33].
Cytoplasmic p16 has only recently been evaluated, having been considered a background factor in
many studies, and so its significance is due for reinterpretation [15]. Some authors have characterized
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p16 expression in CC cell lines and found very opposite results in comparison with ours: exclusively
cytoplasmic p16 in C-33A cells and nuclear/cytoplasmic p16 in SiHa and HeLa cells [18]. Nevertheless,
it is important to mention that they described p16 subcellular location solely in cell lines, which are
just models of disease with many limitations that can influence protein levels and location. In contrast,
our conclusions are supported by observations in tissues. Based on this, our study demonstrates that
cytoplasmic p16 is not an artefact but has important biological and clinical implications. It has been
hypothesized that the binding of p16 to other cytoplasmic proteins could form large molecules that
are unable to pass through the nuclear membrane pores. Among these proteins, AE1 is thought to
be present in gastric and colon cancer cells [15]; while PCNA, MCM6, α/β/γ-actin and α/β-tubulin,
among others, have been observed in a lymphoblastoid cell line [34]. Although it is conceivable that
cytoplasmic p16 interactors are cellular-context-dependent, CDK4 has been proposed as a strong
candidate for sequestering p16 in the cytoplasm [15]. In fact, the interaction between p16 and CDK4
has already been demonstrated via co-immunoprecipitation in SiHa cells [35]. Accordingly, we also
found binding and colocalization of p16 and CDK4 in SiHa cell cytoplasm, which strengthened the
validity of our results. We also detected another p16 interactor already reported in the BioGRID
repository, the complement component 1 Q subcomponent-binding protein (C1QBP), which has been
described as associating with the CDKN2A product to mediate apoptosis [36]. Apart from these, 14 new
interactors of cytoplasmic p16 were also identified here. Importantly, we confirmed the colocalization
of p16 with a protein subset previously involved in carcinogenesis with a specific role in nuclear
shuttling. For instance, BANF1 has been reported to be involved in colony formation, migration and
invasion in CC [37] and in the development of hepatocellular [23] and esophageal squamous cell [24]
carcinomas and gastric cancer [26]. It is also known to interact with a protein which prevents nuclear
accumulation of other proteins, such as β-catenin [38]. Another novel p16 interactor identified here,
AKAP8, dynamically interacts with other proteins during cell cycle progression [39] and appears to
play an important role in promoting lung [27], ovarian [28] and rectal [29] cancers. Moreover, it helps
deliver cyclin D/E to CDK4 [40] and interacts with a kinase which phosphorylates p27 to prevent
its translocation to the nucleus [41]. Finally, we identified AGTRAP, a HIF1α direct target related to
reduced PFS in melanoma [25] and to tumor growth and angiogenesis in Lewis lung carcinoma [42].
Further evaluation is warranted to confirm these observations in larger cohorts of patients,
and to answer many questions that have been raised. For instance, whether p16 sequestration in the
cytoplasm per se is the reason for the failure of its tumor-suppressor function or whether it involves
more complex mechanisms is still to be determined. Since p16 overexpression has been observed
at the invasive front of endometrial, colorectal and basal cell carcinoma, it has been proposed that
cytoplasmic p16 is involved in the dissociation of focal adhesions, and then, related to cell invasion [15],
lymphangiogenesis and lymphatic metastasis [5].
The potential therapeutic value of p16 is also to be elucidated. On the one hand, depletion of
p16 has been shown to promote chemo- and radioresistance in HeLa cells [32]. On the other hand,
it has been suggested that p16 could be a therapeutic target in CC, since its knockdown inhibits cell
proliferation, migration and invasion in SiHa and HeLa cell lines [43] and sensitizes SiHa cells to
cisplatin [35]. However, given the importance of its tumor-suppressor properties in other cell types,
it is not clear how p16 inhibition would affect organism homeostasis. Here, we draw attention to a
potential therapeutic use for p16 that works not by targeting it directly, but by inhibiting the proteins
which sequester it in the cytoplasm. This strategy would be expected to release and translocate p16 to
the nucleus in order to exert its tumor-suppressor function.
Recently, novel proteins, such as PDL1 [44], survivin [45] and SIRT1 [46], have become of interest
as diagnostic or prognostic biomarkers in cervical malignancies. Undoubtedly, these findings are very
important for SCCC clinical management, but their implementation would have economic consequences.
In contrast, our results imply that it is only necessary to evaluate the p16 immunohistochemical pattern
accurately—and since this is already routinely performed—it would not incur any additional cost.
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4. Materials and Methods
4.1. Patient Samples
We analyzed a series of 78 formalin-fixed, paraffin-embedded samples from women diagnosed
with HSIL (n = 29) and SCCC (n = 49). All patients were diagnosed between 1995 and 2015 in
the Pathology Department of the Complejo Hospitalario de Navarra (Pamplona, Spain), Hospital
Universitari de Bellvitge, (L’Hospitalet de Llobregat, Spain), Complejo Asistencial Universitario (León,
Spain), and Hospital Universitari Arnau de Vilanova (Lleida, Spain). Clinical characteristics of SCCC
patients are summarized in Table S3. No clinical follow-up was available for HSIL patients, since they
were all successfully cured by surgery. All tumors were surgically removed and staged according to
their size, histological grade and lymph node involvement. All cases were ensured to harbor at least
70% tumor cells. None of the patients had received radiotherapy or chemotherapy before surgery.
The study was approved by the Navarre Ethics Committee for Clinical Research (PI_2018/75) on
September 30th 2019, procedures were in accordance with the Helsinki declaration, and informed
consent was obtained according to the current Spanish legislation.
4.2. Immunohistochemistry
Sections (4-µm thick) of 29 HSILs and 49 SCCCs were placed on slides and deparaffinized.
After performing antigen retrieval at 37 ◦C for 30 min with the cell conditioning 1 buffer (catalog
number 950–124) at pH 8.4, samples were incubated with the anti-p16 antibody (catalog number
805–4713, clone E6H4) [31] at 1 µg/mL for 28 min at 37 ◦C in a Benchmark XT® Ventana immunostainer
(all reagents and equipment from Roche, Basel, Switzerland). The pattern and intensity of expression
were evaluated blind by two independent observers (T.Z. and E.M.-S.), and ascribed to one of four
categories: 0, no expression; 1, weak expression; 2, moderate expression; and 3, strong expression.
Images were acquired with a Leica DM4000B microscope (Leica, Wetzlar, Germany) and the NIS
Elements v4.30 program (Nikon Instruments, Amsterdam, Netherlands).
4.3. Cell Lines
Two human SCCC cell lines were used in this study, C-33A (an HPV-negative carcinoma) and SiHa
(an HPV16-positive SCCC), both of which were purchased from the American Type Cell Collection
(ATCC, Rockville, MD, USA). Additionally, the HeLa cell line (HPV18-positive cervical adenocarcinoma)
was also obtained from the ATCC. They were all grown in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (all from Life Technologies, Carlsbad, CA, USA), at 37 ◦C
in a humidified atmosphere with 5% CO2. Experiments were performed with Mycoplasma-free and
recently authenticated cell lines at low passage.
4.4. Western Blot
p16 expression levels were checked in both cytoplasmic and nuclear fractions in three CC cell
lines by western blot. Briefly, for subcellular fractionation, C-33A, SiHa and HeLa cells were grown
to 70–80% confluence and lysed with a phosphate-buffered saline (PBS)-based buffer containing
1% NP-40 (Thermo Fisher Scientific, Waltham, MA, USA) and protease inhibitors (Roche, Basel,
Switzerland). Cells were then scraped and centrifuged at 13,000 rpm for 1 min at 4 ◦C. Cytoplasmic
proteins in the supernatant were collected, while pellets were resuspended in 50 µL of lysis buffer
(7M urea, 2M thiourea and 50 mM DTT), incubated on ice for 30 min and sonicated for two cycles
of 20 s each in a Vibra-CellTM 75185 ultrasonic liquid processor (Bioblock Scientific, Illkirch, France).
Finally, samples were centrifuged at 20,000× g for 20 min at 15 ◦C, and nuclear proteins were
collected from the supernatant. Protein concentrations were quantified using the Protein DC kit
(Bio-Rad, Hercules, CA, USA) in an Epoch plate reader (BioTek, Winooski, VT, USA), following the
manufacturers’ recommendations. For western blot, 60 µg of proteins were resolved by SDS-PAGE in
a 15% polyacrylamide gel and transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA,
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USA). The membrane was blocked with 5% non-fat milk and incubated with the anti-p16 antibody
(805–4713, Roche, Basel, Switzerland) at 250 ng/mL overnight and at 4 ◦C. Then, it was incubated with
the secondary anti-mouse antibody (Bio-Rad, Hercules, CA, USA) at 1:2000 for 1 h at room temperature.
The signal was detected with the SuperSignal West Pico Chemiluminescent Substrate kit (Thermo
Fisher Scientific, Waltham, MA, USA) in a ChemiDoc imaging system (Bio-Rad, Hercules, CA, USA)
using ImageLab v5.2 software. The GAPDH (CB1001 from Calbiochem, Burlington, MA, USA) and
Histone H3 (ab17684 from Abcam, Cambridge, UK) antibodies were employed as loading controls for
the cytoplasmic and nuclear fractions, respectively. Finally, the intensity of bands was quantitated by
densitometric analysis using the ImageJ v1.50i program.
4.5. Cell Proliferation and Invasion
To evaluate the proliferative ability of CC cell lines, C-33A, SiHa and HeLa cells were seeded (1 ×
104 cells/well) into 400 µL of medium in an E-plate L8 device (iCELLigence system, ACEA Biosciences,
San Diego, CA, USA), after measuring the background in 100 µL of medium. Two replicates for each
condition were analyzed. Cell attachment, spreading and proliferation were monitored by real-time
cell analysis for 7 days, on the basis of changes in cell-sensor impedance, as previously described [47].
To assess the invasive capability of CC cell lines, cells were starved overnight. Next day, extracellular
matrix layer was prepared by adding 40 µL of Matrigel® (BD Biosciences, Franklin Lake, NJ, USA)
into Transwell® inserts with 8-µm-pore membranes (Sarstedt, Nümbrecht, Germany). After gelling
for 15–30 min at 37 ◦C, starved cells were seeded (1.25 × 105 cells/insert) on the gel layer in FBS-free
medium, and the insert was placed in a well with FBS-containing medium. Cells were allowed to
digest and penetrate the Matrigel® layer as far as the membrane for 72 h. Then, non-invading cells
and the gel layer were removed, and membranes were fixed and stained with a crystal violet solution
containing paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA). Images were taken with a Leica
DMi1 microscope and the Leica Application Suite v4.12 program (Leica, Wetzlar, Germany).
4.6. p16 Native form Identification
In order to explore whether p16 subcellular location depended on the 3D conformation of the
p16+interactors complex, the p16 native form was interrogated in SCCC cell lines. To do this, C-33A and
SiHa cells were scraped and centrifuged at 4000 rpm for 1 min. Pellets were resuspended in 50–200 µL
of non-denaturing lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 2 mM EDTA and protease inhibitors)
and incubated on ice for 5 min. After centrifuging at 8000× g for 10 min at 4 ◦C, proteins contained
in the supernatants were quantified, and 50 µg of native protein Were subjected to PAGE on an 8%
polyacrylamide gel under non-denaturing conditions. Transfer, blocking, incubation with antibodies
and revealing were performed as described above.
4.7. p16 Immunoprecipitation
To identify cytoplasmic p16 interactors, p16 was first immunoprecipitated from SiHa cells. Briefly,
cells were grown to 70–80% confluence, lysed with a home-made IP buffer (50 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 1% Triton and protease inhibitors) and centrifuged at maximum speed for 10 min.
Proteins contained in the supernatants were quantified as described above, and three aliquots were
separated: 50 µg Were denatured and stored to check the input by western blot; 5 mg Were incubated
with 10 µg of anti-p16 antibody (ab108349, Abcam, Cambridge, UK); and 5 mg Were incubated
with an irrelevant antibody (rabbit IgG, 10500C, Thermo Fisher Scientific, Waltham, MA, USA).
Incubations were performed overnight at 4 ◦C in a rotating wheel. The next day, 30 µL of protein
A/G-coated magnetic beads (Thermo Fisher Scientific, Waltham, MA, USA) Were added to each sample
and incubated for 2 h at room temperature to allow them to bind to the antigen-antibody complex.
Extracts were sequentially washed three times with IP buffer using a magnetic stand. Finally, 30 µL of
IP buffer and 10 µL of Laemmli buffer 4×Were added, and samples were heated at 95 ◦C for 5 min
to denature and unbind the magnetic beads. A magnetic stand was used to remove magnetic beads.
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A small 5-µL fraction of the eluted extract was separated to check immunoprecipitation efficiency
by western blot, using the α-tubulin antibody (T-6074 from Sigma-Aldrich, St Louis, MO, USA) as a
loading control, while 15 µL Were subjected to mass spectrometry.
4.8. Mass Spectrometry and Bioinformatic Analysis
SiHa protein extracts incubated with the anti-p16 and the IgG antibodies were analyzed by
LC-MS/MS using two parallel strategies: i) extracts were subjected to SDS-PAGE in a Criterion™ TGX
Stain-Free™ protein gel (Bio-Rad, Hercules, CA, USA), and bands were individually excised from the
gel and then digested; ii) extracts were directly digested in solution. In both cases, protein extracts were
trypsin-digested and cleaned with ZipTip. Resulting samples were examined in a Triple-TOF 5600+
(Sciex, Framingham, MA, USA) coupled to a NanoLC Ultra 1D Plus nanochromatograph (Eksigent,
Dublin, CA, USA), as previously described [48]. MS/MS data were acquired using Analyst 1.7.1 (Sciex,
Framingham, MA, USA) and spectra files were processed with Protein Pilot Software v.5.0 (Sciex,
Framingham, MA, USA) using the Paragon™ algorithm for database searching, Progroup™ for data
grouping, and searched against the concatenated target-decoy UniProt human proteome reference
database (Proteome ID: UP000005640, 73045 proteins, April 2018) plus Human papillomavirus type
16 database (Proteome ID: UP000009251, 9 proteins, April 2018). The FDR was estimated using a
non-linear fitting method and the results displayed were those for a global FDR of 1% or better.
Proteins unequivocally detected in both workflows in the extract with the anti-p16 antibody but not
present in the anti-IgG sample and with an FDR < 1% were considered to be potential p16 interactors.
Their biological functions were interrogated using the UniprotKB/Swiss-Prot (https://www.uniprot.org/)
database. Additionally, the p16 interactors identified here were compared with those available in
the interaction repository BioGRID (Biological General Repository for Interaction Datasets, v3.5.173,
https://thebiogrid.org/) [49].
4.9. Immunofluorescence
In order to confirm p16 expression pattern in cultured SCCC cells and to assess colocalization of
cytoplasmic p16 and its potential interactors, cells were seeded on coverslips and allowed to attach
overnight. Cells were then fixed with 4% paraformaldehyde, blocked with 5% FBS in PBS at room
temperature for 1 h, and incubated at 4 ◦C overnight with primary antibodies: anti-p16 (805-4713, Roche,
Basel, Switzerland) at 250 ng/mL, and anti-CDK4 (ab108357, Abcam, Cambridge, UK), anti-BANF1
(CSB-PA002550LA01HU), anti-AKAP8 (STJ91533) or anti-AGTRAP (CSB-PA744194LA01HU) (all from
Antibodyplus, Inc., Brookline, MA, USA), at 1:150. All samples were simultaneously incubated
with AlexaFluor 488 anti-mouse and AlexaFluor 568 anti-rabbit (1:200) (Life Technologies, Carlsbad,
CA, USA) at room temperature for 1 h. Finally, samples were mounted on slides with DAPI
to counterstain nuclei. Images were acquired with a Leica DM4000B microscope (Leica, Wetzlar,
Germany), using the NIS Elements v4.30 program (Nikon Instruments, Amsterdam, Netherlands),
and excitation/emission wavelengths of 340–380/425 nm, 450–490/525 nm, and 560/40–645/75 nm for
blue, green and red, respectively.
4.10. Statistical Analysis
Demographic, clinical and pathological data were summarized as frequencies (and percentages)
and means (and ranges) ± standard error of the mean, as appropriate. All statistical analyses were
carried out using IBM SPSS Statistics v25. Immunohistochemical expression levels in HSIL and SCCC
samples, as well as differences in cell line proliferation, were compared using the Mann-Whitney test.
Association between clinical variables and p16 expression or location was tested using a χ2 contingency
test. Kaplan-Meier plots and log-rank tests were used to examine the association of p16 expression
and location, age, stage and vascular invasion with PFS and OS in SCCC patients. A multivariate
Cox regression model was fitted to test the independent contribution of each variable to the patient’s
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outcome after adjusting. Hazard ratios and 95% confidence intervals were used to estimate the effect
of each variable on the outcome.
5. Conclusions
In conclusion, we have gained further insight into the paradox of p16 overexpression in CC:
it is expressed at high levels, but not located where it would act as a tumor-suppressor protein.
We propose then that exploring p16 subcellular location can provide more useful information regarding
anti-tumor activity than p16 overall expression examination. In particular, cytoplasmic p16, which is
sequestered by novel proteins identified here for the first time, is more frequently observed in SCCC
than HSIL and is associated with a worse outcome in SCCC. Therefore, the ratio of cytoplasmic to
nuclear p16 and the absence of nuclear p16 could be independent biomarkers for SCCC diagnosis and
prognosis, respectively.
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